Squawk Box

COVID-19 vaccine developer Johnson & Johnson (NYSE: JNJ) paused an ongoing trial Monday due to an unexplained illness, although it's unknown if the individual in question was given the vaccine or a placebo, J&J CFO Joseph Wolk said on CNBC's "Squawk Box." What...

Jim Cramer shared his thoughts on several big stocks Tuesday on CNBC's “Squawk Box.” Cramer on Bank Earnings: When asked about JPMorgan Chase's (NYSE: JPM) third-quarter earnings, Cramer said the company looked very good. “I think people aren’t borrowing that...

The U.S. presidential election is weeks away, and there will be "surprises here and there" that could add new volatility to the markets, B. Riley FBR Chief Global Market Strategist Mark Grant said Monday on CNBC's "Squawk Box." What Happened: The presidential election is...

President Donald Trump was taken to the Walter Reed Medical Center on Friday to treat his coronavirus diagnosis. While at Walter Reed, Trump was given several treatments including an experimental antibody treatment from Regeneron Pharmaceuticals (NASDAQ: REGN) and remdesivir, an anti-viral from...

CNBC's Jim Cramer has been bashing SPACs on Twitter and his show this week. That drew attention from the so-called SPAC King Chamath Palihapitiya. What Happened: Cramer recently highlighted Spartan Energy Acquisition (NYSE: SPAQ), a SPAC merging with Fisker. Cramer compared Henrik Fisker and...

Global health care giant Johnson & Johnson (NYSE: JNJ) is proceeding with a Phase 3 trial of its coronavirus vaccine, and it believes a single dose will offer protection against the virus "very quickly," J&J Chief Scientific Officer Dr. Paul Stoffels said on CNBC's "...

Coronavirus vaccine developer AstraZeneca plc (NYSE: AZN) said Tuesday that a Phase 3 trial being conducted with Oxford University has been put on hold for a safety review. Several experts said they're not overly concerned the development will derail the likelihood of a COVID-19...

Johnson & Johnson (NYSE: JNJ) plans on enrolling up to 60,000 people in a coronavirus vaccine trial, likely as part of a global development and regulatory approval strategy, ex-FDA Commissioner Scott Gottlieb said Friday on CNBC's "Squawk Box." J&J's Global Approval...

Retail behemoth Walmart Inc (NYSE: WMT) reported Tuesday morning with such a strong second-quarter earnings beat that it even shocked a former top Bentonville executive. Walmart Q2 Recap: Walmart said it earned $1.56 per share in the second quarter on revenue of $137.74 billion versus expectations...

Tesla Inc (NASDAQ: TSLA) announced Tuesday a 5-for-1 stock split and this is consistent with CEO Elon Musk's belief in looking out for small investors, The Wall Street Journal's Tim Higgins said on CNBC. The 'Little Guy' Built Tesla: Musk's vision since taking Tesla public...

Reports of Amazon.com, Inc.'s (NASDAQ: AMZN) interest in taking over empty store space in Simon Property Group Inc (NYSE: SPG) malls are "absolutely true," Scott Crowe, chief investment strategist at Center Square Investment Management, said on CNBC. What Happened: Simon Properties,...

Electric vehicle manufacturer Tesla Inc (NASDAQ: TSLA) is "running on borrowed time," as it can only rely on regulatory tax credits for so long, according to GLJ Research's Gordon Johnson. What Happened: Tesla is making a profit on tax credits, but the argument could be made that...

Data from the U.S. Transportation Security Administration shows total passengers moving through airports (including airline workers and airport employees) is down around 73% year-over-year. United Airlines Holdings Inc (NASDAQ: UAL) is seeing its revenue down even more at 83%, CEO Scott Kirby...

The digital economy is not only responsible for creating thousands of new jobs, but helping struggling industries remain relevant, O'Shares ETFs Chairman and "Shark Tank" host Kevin O'Leary said on CNBC's "Squawk Box." What Happened: The wine industry is as...

The U.S. government awarded Novavax, Inc. (NASDAQ: NVAX) $1.6 billion in funding to support its COVID-19 vaccine, and the company is confident it has the capability to produce 100 million doses by the end of the year, Novavax CEO Stanley Erck said on CNBC's "Squawk Box." Novavax...